PMID- 27464024
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20220321
IS  - 1414-431X (Electronic)
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 49
IP  - 8
DP  - 2016 Jul 25
TI  - Combination therapy of orally administered glycyrrhizin and UVB improved 
      active-stage generalized vitiligo.
LID - S0100-879X2016000800605 [pii]
LID - 10.1590/1414-431X20165354 [doi]
LID - e5354
AB  - Glycyrrhizin has been used clinically for several years due to its beneficial 
      effect on immunoglobulin E (IgE)-induced allergic diseases, alopecia areata and 
      psoriasis. In this study, glycyrrhizin, ultraviolet B light (UVB) or a 
      combination of both were used to treat active-stage generalized vitiligo. One 
      hundred and forty-four patients between the ages of 3 and 48 years were divided 
      into three groups: group A received oral compound glycyrrhizin (OCG); group B 
      received UVB applications twice weekly, and group C received OCG+UVB. Follow-ups 
      were performed at 2, 4, and 6 months after the treatment was initiated. The 
      Vitiligo Area Scoring Index (VASI) and the Vitiligo Disease Activity (VIDA) 
      instrument were used to assess the affected body surface, at each follow-up. 
      Results showed that 77.1, 75.0 and 87.5% in groups A, B and C, respectively, 
      presented repigmentation of lesions. Responsiveness to therapy seemed to be 
      associated with lesion location and patient compliance. Adverse events were 
      limited and transient. This study showed that, although the three treatment 
      protocols had positive results, OCG and UVB combination therapy was the most 
      effective and led to improvement in disease stage from active to stable.
FAU - Mou, K H
AU  - Mou KH
AD  - Department of Dermatology, The First Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Han, D
AU  - Han D
AD  - Department of Dermatology, The First Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Liu, W L
AU  - Liu WL
AD  - Department of Dermatology, The First Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Li, P
AU  - Li P
AD  - Center for Translational Medicine, The First Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - 0 (Dermatologic Agents)
RN  - 0 (Tablets)
RN  - 6FO62043WK (Glycyrrhizic Acid)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy/methods
MH  - Dermatologic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Glycyrrhizic Acid/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Skin Pigmentation
MH  - Tablets
MH  - Treatment Outcome
MH  - Ultraviolet Therapy/*methods
MH  - Vitiligo/classification/*therapy
MH  - Young Adult
PMC - PMC4964896
EDAT- 2016/07/28 06:00
MHDA- 2017/06/13 06:00
PMCR- 2016/07/25
CRDT- 2016/07/28 06:00
PHST- 2016/02/19 00:00 [received]
PHST- 2016/05/30 00:00 [accepted]
PHST- 2016/07/28 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/06/13 06:00 [medline]
PHST- 2016/07/25 00:00 [pmc-release]
AID - S0100-879X2016000800605 [pii]
AID - 10.1590/1414-431X20165354 [doi]
PST - ppublish
SO  - Braz J Med Biol Res. 2016 Jul 25;49(8):e5354. doi: 10.1590/1414-431X20165354.